哌拉西林/他唑巴坦治疗细菌感染的临床评价

CLINICAL EVALUATION OF PIPERACILLIN-TAZOBACTAM TREATMENT IN ACUTE BACTERIAL INFECTION

目的 :评价哌拉西林 /他唑巴坦治疗急性细菌性感染的安全性和有效性。方法 :131例患者随机分为哌拉西林 /他唑巴坦组 6 7例和特美汀组 6 4例。哌拉西林 /他唑巴坦组每日 8～ 12 g ,疗程 7～ 14d ;特美汀组每日 9 6～ 12 .8g ,疗程 7～ 14d。 结果 :哌拉西林 /他唑巴坦和特美汀治疗组细菌感染痊愈率为6 2 7%和 6 0 9% ,有效率为 89 6 %和 84 4 % ,细菌清除率为 91 5%和 89.1% ,两组不良反应发生率为11 9%和 6 2 5% ,两组比较差异无显著性。结论 :哌拉西林 /他唑巴坦是一种安全有效的抗感染药物。

Objective:To evaluate clinical efficacy and safety of piperacillin tazobactam treatment in acute bacterial infections.Methods:In this study 131 patients were randomized to receive either piperacillin tazobactam 8～12g/d or ticarcillin clavulanate 9.6～12.8g/d for 7～14 days.Sixty seven patients received piperacillin tazobactam and 64 patients received ticarcillin clavnlanate.Results:The cure rates in piperacillin tazobactom and ticarcillin clavulanate groups were 62.7% and 60.9% respectively and the efficary rates 89.6% and 84.4% respectively.Bacterial eradication rates were 91.5% and 89.1% respectively.The side effect rates were 11.9% and 6.25% respectively.There were no significant differences between two groups.Conclusion:Piperacillin tazobactam is a kind of safe and effective anti infection medicine.